The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
-
REGULATORY CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
-
BUSINESS Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
-
REGULATORY Japan, US, Europe Trade Groups Forge United Front against Govt PMP Plan, Supportive of Negative List: Chuikyo
November 30, 2017
-
BUSINESS Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
-
REGULATORY New Plan Would Reduce Number of PMP-Eligible Products by 40-50%: MHLW Estimate
November 29, 2017
-
BUSINESS Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
November 28, 2017
-
ORGANIZATION PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
-
REGULATORY Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
-
REGULATORY Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
-
TRENDS Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
November 22, 2017
-
BUSINESS Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market
November 21, 2017
-
REGULATORY Govt Plans to Apply 5 Price Bands for Listed Generics in “Off-Year” Revisions, Maintain 50% Rule for 1st Generics in April
November 20, 2017
-
REGULATORY Govt Plans Tiered PMP for Smaller Scope of Products, Post-Z2 Rule for LLPs
November 17, 2017
-
BUSINESS Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
November 16, 2017
-
REGULATORY Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22
November 15, 2017
-
ORGANIZATION Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
-
REGULATORY Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
-
BUSINESS Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
-
ACADEMIA In Renewed Attempt, Tokushima Univ. Starts IIT for Eisai-Dropped ALS Drug Candidate
November 9, 2017
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…